Please assess the completion status of the following clinical trial:

Trial Title: A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and non-pregnant or sterile women ages 45 and older~* Hypertriglyceridemia~* On statin therapy for at least four weeks~* Either having established cardiovascular disease or at high risk for cardiovascular disease~Exclusion Criteria:~* Severe heart failure~* Any life-threatening disease other than cardiovascular disease~* Active severe liver disease~* Hemoglobin A1c \>10.0%~* Poorly controlled hypertension~* Planned coronary intervention (such as stent placement or heart bypass) or any non-cardiac major surgical procedure~* Known familial lipoprotein lipase deficiency (Fredrickson Type I), apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia (Fredrickson Type III)~* Known hypersensitivity to the study product, fish and/or shellfish, or placebo~* History of acute or chronic pancreatitis~* Patients are excluded if using the following medications:~  * PCSK9 inhibitors~ * niacin \>200 mg/day or fibrates;~ * any omega-3 fatty acid medications ;~ * dietary supplements containing omega-3 fatty acids (e.g., flaxseed oil, fish oil, krill oil, or algal oil);~ * bile acid sequestrants

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMR101 (Type: EXPERIMENTAL): AMR101 (icosapent ethyl) + statin therapy, daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo + statin therapy, daily

Based on this trial design, predict the completion outcome and termination type (if applicable).